Summit Therapeutics (SMMT) Stock News

Summit Therapeutics (NASDAQ:SMMT) announced that data from the Phase III HARMONi-6 trial of ivonescimab will be featured at the ESMO 2025 Presidential Symposium on October 19, 2025. The trial, conducted in China by Akeso, demonstrated a statistically significant improvement in progression-free survival (PFS) when combining ivonescimab with chemotherapy versus tislelizumab plus chemotherapy in first-line treatment of squamous non-small cell lung cancer (NSCLC).

This marks the first known Phase III trial showing superiority over a PD-(L)1 inhibitor combined with chemotherapy in NSCLC. The PFS benefit was observed in both PD-L1-positive and negative tumors, with no new safety concerns. Summit is currently conducting the global HARMONi-3 trial with registrational intent for the US and other regions.

Summit Therapeutics (NASDAQ:SMMT) announced updated results from the global Phase III HARMONi trial for ivonescimab, a novel PD-1/VEGF bispecific antibody. The trial demonstrated an improved overall survival (OS) hazard ratio of 0.78 with a nominal p-value of 0.0332. The median OS was 16.8 months for ivonescimab plus chemotherapy versus 14.0 months for placebo plus chemotherapy.

Key findings include statistically significant progression-free survival (PFS) with a hazard ratio of 0.52 (p0.00001), and higher overall response rates in the ivonescimab arm (45%) compared to placebo (34%). North American patients showed particularly strong results with an OS hazard ratio of 0.70. The drug demonstrated consistent benefits across Western and Asian populations, with a favorable safety profile.

Summit Therapeutics (NASDAQ:SMMT) announced updated data from its Phase III HARMONi trial for ivonescimab plus chemotherapy in EGFR-mutated NSCLC patients. In the longer-term follow-up analysis of Western patients, the treatment showed an improved overall survival (OS) trend with a nominal p-value of 0.0332 versus chemotherapy alone.

Key findings include median OS of 16.8 months for ivonescimab plus chemotherapy vs. 14.0 months for placebo plus chemotherapy. North American patients showed particularly promising results with OS hazard ratio of 0.70. The treatment demonstrated statistically significant progression-free survival (PFS) improvement with hazard ratio of 0.52 (p0.00001)45% vs. 34% for placebo.

The safety profile remained manageable with 7.3% discontinuation rate due to treatment-related adverse events.

Summit Therapeutics (NASDAQ: SMMT) has announced a conference call on September 8, 2025, at 8:00 AM ET to discuss data from their Phase III clinical trial, HARMONi. The presentation will be featured in the Presidential Symposium at the 2025 World Conference on Lung Cancer (WCLC) in Barcelona.

The HARMONi trial is evaluating ivonescimab plus platinum-doublet chemotherapy versus placebo in patients with EGFR-mutated non-small cell lung cancer (NSCLC) who have progressed after treatment with 3rd generation EGFR TKI. The presentation will be accessible through Summit's website, with an archived version available afterward.

Summit Therapeutics (NASDAQ: SMMT) announced that data from their Phase III HARMONi trial of ivonescimab will be presented at the WCLC 2025 Presidential Symposium on September 7, 2025. The trial evaluated ivonescimab plus chemotherapy versus placebo in EGFR-mutated non-small cell lung cancer (NSCLC) patients.

The study demonstrated statistically significant improvement in progression-free survival with a hazard ratio of 0.52 (p<0.00001). While overall survival showed a positive trend with a hazard ratio of 0.79, it did not reach statistical significance (p=0.057). The presentation will be delivered by Dr. Jonathan Goldman from UCLA, marking ivonescimab's second consecutive year at the WCLC Presidential Symposium.

Summit Therapeutics (NASDAQ:SMMT) reported significant progress in Q2 2025, highlighted by positive results from multiple Phase III trials of ivonescimab. The HARMONi trial demonstrated statistically significant improvement in progression-free survival with a hazard ratio of 0.52 (p<0.00001) in EGFR-mutated NSCLC patients.

The company's financial position showed $297.9 million in cash and investments as of June 30, 2025, down from $412.3 million in December 2024. A significant non-cash expense of $466.6 million was recorded due to stock option modifications. The company established a new $360 million ATM offering facility with J.P. Morgan.

Key operational highlights include positive interim survival analysis in the HARMONi-2 study, NMPA approval in China for first-line PD-L1 positive advanced NSCLC, and a new clinical collaboration with Revolution Medicines for RAS(ON) inhibitor combinations.

Summit Therapeutics (NASDAQ: SMMT) has granted inducement stock options to seven new employees, totaling 71,275 shares of common stock. The options were awarded on June 2, 2025, with a ten-year term and an exercise price of $17.72 per share, matching the company's closing stock price on the grant date. These options will vest in equal annual installments over four years and were granted from a pre-approved equity incentive pool established on January 22, 2025. The awards were made in accordance with Nasdaq Listing Rule 5635(c)(4) and received approval from Summit's Compensation Committee.

Summit Therapeutics (NASDAQ: SMMT) has announced its participation in the 46th Annual Goldman Sachs Global Healthcare Conference in Miami, Florida. The company's management team will deliver a fireside chat presentation on June 9, 2025, at 1:20 PM ET. During the presentation, they will provide a corporate overview and updates on their progress, with particular focus on ivonescimab, their innovative investigational bispecific antibody. The presentation will be accessible live through Summit's website www.smmttx.com, with an archived version available afterward.

Summit Therapeutics announced positive topline results from HARMONi, a global Phase III trial evaluating ivonescimab plus chemotherapy in EGFR-mutated non-small cell lung cancer (NSCLC) patients. The study met its primary endpoint, showing a 48% reduction in disease progression or death risk compared to chemotherapy alone (HR=0.52, p<0.00001). The trial also showed a positive trend in overall survival with a hazard ratio of 0.79, though not reaching statistical significance (p=0.057). The safety profile was manageable, with 56.9% of patients in the treatment arm experiencing Grade 3+ adverse events versus 50.0% in the control arm. The study included patients from both Asian (62%) and Western (38%) countries, demonstrating consistent benefits across regions. Summit is considering the timing of a BLA filing, noting FDA's requirement for statistically significant overall survival benefit for marketing authorization.